Innoviva, Inc. (INVA)
20.84
-0.06
(-0.29%)
USD |
NASDAQ |
Sep 15, 16:00
20.85
+0.01
(+0.05%)
After-Hours: 20:00
Innoviva Enterprise Value : 1.204B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 1.204B |
| September 14, 2026 | 1.209B |
| September 11, 2026 | 1.191B |
| September 10, 2026 | 1.188B |
| September 09, 2026 | 1.225B |
| September 08, 2026 | 1.241B |
| September 04, 2026 | 1.240B |
| September 03, 2026 | 1.241B |
| September 02, 2026 | 1.241B |
| September 01, 2026 | 1.222B |
| August 31, 2026 | 1.199B |
| August 28, 2026 | 1.214B |
| August 27, 2026 | 1.213B |
| August 26, 2026 | 1.233B |
| August 25, 2026 | 1.228B |
| August 24, 2026 | 1.218B |
| August 21, 2026 | 1.221B |
| August 20, 2026 | 1.216B |
| August 19, 2026 | 1.251B |
| August 18, 2026 | 1.234B |
| August 17, 2026 | 1.213B |
| August 14, 2026 | 1.230B |
| August 13, 2026 | 1.198B |
| August 12, 2026 | 1.202B |
| August 11, 2026 | 1.198B |
| Date | Value |
|---|---|
| August 10, 2026 | 1.193B |
| August 07, 2026 | 1.180B |
| August 06, 2026 | 1.224B |
| August 05, 2026 | 1.180B |
| August 04, 2026 | 1.206B |
| August 03, 2026 | 1.199B |
| July 31, 2026 | 1.214B |
| July 30, 2026 | 1.232B |
| July 29, 2026 | 1.262B |
| July 28, 2026 | 1.275B |
| July 27, 2026 | 1.238B |
| July 24, 2026 | 1.248B |
| July 23, 2026 | 1.231B |
| July 22, 2026 | 1.247B |
| July 21, 2026 | 1.258B |
| July 20, 2026 | 1.236B |
| July 17, 2026 | 1.268B |
| July 16, 2026 | 1.304B |
| July 15, 2026 | 1.281B |
| July 14, 2026 | 1.270B |
| July 13, 2026 | 1.304B |
| July 10, 2026 | 1.306B |
| July 09, 2026 | 1.303B |
| July 08, 2026 | 1.320B |
| July 07, 2026 | 1.307B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zevra Therapeutics, Inc. | 471.26M |
| Collegium Pharmaceutical, Inc. | 1.778B |
| CorMedix, Inc. | 490.50M |
| ANI Pharmaceuticals, Inc. | 1.891B |
| Corcept Therapeutics, Inc. | 11.66B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -83.42M |
| Revenue (Quarterly) | 123.05M |
| Total Expenses (Quarterly) | 206.47M |
| EPS Diluted (Quarterly) | -1.136 |
| Gross Profit Margin (Quarterly) | 73.64% |
| Profit Margin (Quarterly) | -67.80% |
| Earnings Yield | 19.70% |
| Operating Earnings Yield | 9.50% |
| Normalized Earnings Yield | 10.97 |